Logo

BioTime Acquires Asterias Biotherapeutics with Two of its Clinical Stage Cell Therapy Candidates

Share this
BioTime Acquires Asterias Biotherapeutics with Two of its Clinical Stage Cell Therapy Candidates

BioTime Acquires Asterias Biotherapeutics with Two of its Clinical Stage Cell Therapy Candidates

Shots:
  • Asterias to receive 0.71 share- for each of its share in BioTime making it an ownership of 16.2%. Biotime to get hold of all stock of Asterias along with two clinical stage candidates i.e. OPC1 & VAC2
  • The focus of the acquisition is to develop & commercialize novel therapies in fields of Immuno-oncology & Neurology
  • OPC1 is a therapy utilizing oligodendrocyte progenitor cells (OPCs)- is currently evaluated in P-II for the treatment of Severe Spinal Cord Injury. VAC2 is an immunotherapy candidate- currently evaluated in P-I for the treatment of NSCLC in collaboration with Cancer Research UK
Ref: BioTime | Image: Commons Wikimedia

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions